Anthropic to Develop Drugs for Neglected Diseases as AI Workbench Targets Science
Updated
Updated · The Verge · Jul 3
Anthropic to Develop Drugs for Neglected Diseases as AI Workbench Targets Science
3 articles · Updated · The Verge · Jul 3
Summary
Anthropic said it will develop its own drugs, with life sciences chief Eric Kauderer-Abrams saying the company will target treatments for neglected diseases.
Claude Science, unveiled this week as an AI workbench for scientists, is meant to pull fragmented tools and datasets into one environment and support research with generated figures and visuals.
The move makes Anthropic one of the clearest frontier AI companies to publicly pursue drug development itself, even as it already sells software to biotech and pharma customers.
Experts said AI can speed molecule design, data analysis and other discovery steps, but experimental work, animal studies and human trials still require heavy spending and years of testing.
No AI-designed drug has yet reached market through FDA approval, and any payoff for Anthropic is likely at least a decade away despite its recent biology hires and wet-lab buildout.
As Anthropic sells AI tools while also making drugs, can it avoid fatally competing with its own customers?
AI can design drugs in months, but can it solve the 90% failure rate in human clinical trials?
Why is a $380B AI giant targeting 'neglected' diseases, a notoriously unprofitable area for drug development?
Anthropic Enters Drug Discovery: How Claude Science Aims to Accelerate Biomedical Innovation
Overview
On June 30, 2026, Anthropic announced its entry into scientific research and drug discovery, launching Claude Science to integrate artificial intelligence into biological research. Claude Science aims to streamline tedious scientific processes by offering advanced tools for antibiotic design and vaccine target prediction, addressing challenges like fragmented databases and diverse file formats. Anthropic’s move is driven by rapid technology adoption in life sciences and strong market demand for innovative R&D solutions. By actively participating in research, Anthropic gains real-world data to improve its AI models, positioning itself as both a technology provider and a key player in accelerating drug discovery.